HilleVax, Inc. financial data

Symbol
HLVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Harrison Ave, Suite 500, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.28 K % -42.2%
Debt-to-equity 28.4 % +72.9%
Return On Equity -56.2 % -30.1%
Return On Assets -43.8 % -18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.7 M shares +26.6%
Common Stock, Shares, Outstanding 49.1 M shares +29.6%
Entity Public Float 258 M USD +13.3%
Common Stock, Value, Issued 5 K USD +25%
Weighted Average Number of Shares Outstanding, Basic 48.5 M shares +28.4%
Weighted Average Number of Shares Outstanding, Diluted 48.5 M shares +28.4%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 29.4 M USD +47.6%
Operating Income (Loss) -154 M USD -86.3%
Nonoperating Income (Expense) 10.7 M USD +43.4%
Net Income (Loss) Attributable to Parent -144 M USD -20.8%
Earnings Per Share, Basic -3.3 USD/shares -195%
Earnings Per Share, Diluted -3.3 USD/shares -195%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 141 M USD -45.9%
Marketable Securities, Current 132 M USD
Assets, Current 281 M USD +4.17%
Property, Plant and Equipment, Net 13.6 M USD +30.1%
Operating Lease, Right-of-Use Asset 17.8 M USD -6.15%
Other Assets, Noncurrent 23 K USD +4.55%
Assets 314 M USD +4.39%
Accounts Payable, Current 2.98 M USD +70.9%
Employee-related Liabilities, Current 2.05 M USD +23.6%
Accrued Liabilities, Current 19.1 M USD +9.94%
Liabilities, Current 25.7 M USD +33.6%
Operating Lease, Liability, Noncurrent 22.4 M USD -2.67%
Other Liabilities, Noncurrent 1.7 M USD +128%
Liabilities 75.3 M USD +30%
Accumulated Other Comprehensive Income (Loss), Net of Tax -950 K USD -237%
Retained Earnings (Accumulated Deficit) -435 M USD -49.2%
Stockholders' Equity Attributable to Parent 239 M USD -1.71%
Liabilities and Equity 314 M USD +4.39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33 M USD -107%
Net Cash Provided by (Used in) Financing Activities 15.1 M USD +18728%
Net Cash Provided by (Used in) Investing Activities -57.7 M USD -1832%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 49.7 M shares +26.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -75.6 M USD -301%
Interest Paid, Excluding Capitalized Interest, Operating Activities 382 K USD +99%
Deferred Tax Assets, Valuation Allowance 54.5 M USD +102%
Deferred Tax Assets, Gross 58.4 M USD +86.2%
Operating Lease, Liability 25.9 M USD +12.3%
Depreciation 1.33 M USD +45500%
Payments to Acquire Property, Plant, and Equipment 153 K USD -94.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -144 M USD -21.1%
Lessee, Operating Lease, Liability, to be Paid 35.1 M USD -9.09%
Property, Plant and Equipment, Gross 14.9 M USD +42.8%
Operating Lease, Liability, Current 3.49 M USD +9087%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.69 M USD +2.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.69 M USD +2.87%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.24 M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.78 M USD +2.6%
Deferred Tax Assets, Operating Loss Carryforwards 10.3 M USD +48.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50 M shares 0%
Unrecognized Tax Benefits 959 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.86 M USD +2.01%
Operating Lease, Payments 896 K USD +2.87%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.94 M USD -11.6%
Share-based Payment Arrangement, Expense 16.1 M USD +200%
Interest Expense 2.67 M USD +48.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%